Abstract
Pronounced immune escape by the SARS-CoV-2 Omicron variant has resulted in large numbers of individuals with hybrid immunity, generated through a combination of vaccination and infection. Based primarily on circulating neutralizing antibody (NAb) data, concerns have been raised that omicron breakthrough infections in triple-vaccinated individuals result in poor induction of omicron-specific immunity, and that a history of prior SARS-CoV-2 in particular is associated with profound immune dampening. Taking a broader and comprehensive approach, we characterized mucosal and blood immunity to both spike and non-spike antigens following BA.1/BA.2 infections in triple mRNA-vaccinated individuals, with and without a history of previous SARS-CoV-2 infection. We find that the majority of individuals increase BA.1/BA.2/BA.5-specific NAb following infection, but confirm that the magnitude of increase and post-omicron titres are indeed higher in those who were infection-naive. In contrast, significant increases in nasal antibody responses are seen regardless of prior infection history, including neutralizing activity against BA.5 spike. Spike-specific T cells increase only in infection-naive vaccinees; however, post-omicron T cell responses are still significantly higher in previously-infected individuals, who appear to have maximally induced responses with a CD8+ phenotype of high cytotoxic potential after their 3rd mRNA vaccine dose. Antibody and T cell responses to non-spike antigens also increase significantly regardless of prior infection status, with a boost seen in previously-infected individuals to immunity primed by their first infection. These findings suggest that hybrid immunity induced by omicron breakthrough infections is highly dynamic, complex, and compartmentalised, with significant immune enhancement that can help protect against COVID-19 caused by future omicron variants.
Competing Interest Statement
Susanna J Dunachie is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she receives a fee. Oxford University has entered a joint COVID-19 vaccine development partnership with AstraZeneca. Gavin Screaton sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. All other authors have declared no competing interests.
Funding Statement
This work was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, UKRI as part of 'Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway' MR/W02067X/1 and UKRI as part of 'PITCH2 - Protective Immunity through T Cells in Healthcare workers 2' MR/X009297/1, with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and The National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number COV19- RECPLAS). Eleanor Barnes and Paul Klenerman are NIHR Senior Investigators and Paul Klenerman. is funded by WT109965MA. Susanna J. Dunachie is funded by an NIHR Global Research Professorship (NIHR300791). Rebecca P. Payne is funded by a Career Re-entry Fellowship (204721/Z/16/Z). Christopher J.A. Duncan was supported by fellowships from Wellcome (211153/Z/18/Z) and the Medical Research Council (MR/X001598/1). This study was supported by the NIHR Newcastle Clinical Research Facility. Tao Dong, Juthathip Mongkolsapaya and Gavin Screaton are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002), Schmidt Futures, the Red Avenue Foundation and the Oak Foundation. The Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). Lance Turtle is supported by the Wellcome Trust (grant number 205228/Z/16/Z) and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with UK Health Security Agency (UKHSA), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. Dan Wootton is supported by an NIHR Advanced Fellowship in Liverpool. Miles Carroll, Stephanie Longet, Lance Turtle, and Tom Tipton are supported by U.S. Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085. The Sheffield Teaching Hospitals Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS) was supported by the British Heart Foundation (PG/11/116/29288). The STHObS Chief Investigator Allan Laurie is supported by a British Heart Foundation Senior Basic Science Research fellowship (FS/18/52/33808). We gratefully acknowledge financial support from the UK Department of Health and Social Care via the Sheffield NIHR Clinical Research Facility award to the Sheffield Teaching Hospitals Foundation NHS Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Berkshire Research Ethics Committee of the Health Research Authority gave ethical approval for this work (REC reference 18/YH/0441). The North West - Liverpool Central Research Ethics Committee of the Health Research Authority gave ethical approval for this work (REC reference 16/NW/0170). The Yorkshire & The Humber - Sheffield Research Ethics Committee gave ethical approval for this work (REC references 16/YH/0247, 18/YH/0441).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
All code and data used to undertake the Uniform Manifold Approximation and Projection (UMAP) analysis can be found on Github. An anonymised copy of all data used in this study will be made available on the Open Science Framework.
